Literature DB >> 30394566

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Nicholas J Short1, Elias Jabbour1, Maher Albitar2, Marcos de Lima3, Lia Gore4, Jeffrey Jorgensen1, Aaron C Logan5, Jae Park6, Farhad Ravandi1, Bijal Shah7, Jerald Radich8, Hagop Kantarjian1.   

Abstract

Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.
© 2018 Wiley Periodicals, Inc.

Entities:  

Mesh：

Year:  2018        PMID： 30394566      PMCID： PMC6572728          DOI： 10.1002/ajh.25338

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  74 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

Review 2.  Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.

Authors:  Brent L Wood
Journal:  Cytometry B Clin Cytom       Date:  2015-05-29       Impact factor: 3.058

3.  Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation.

Authors:  Joaquín Sánchez; Josefina Serrano; Pedro Gómez; Francisco Martínez; Carmen Martín; Luis Madero; Concepción Herrera; J Manuel García; Javier Casaño; Antonio Torres
Journal:  Br J Haematol       Date:  2002-03       Impact factor: 6.998

4.  Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Authors:  Olga Sala Torra; Megan Othus; David W Williamson; Brent Wood; Ilan Kirsch; Harlan Robins; Lan Beppu; Margaret R O'Donnell; Stephen J Forman; Frederick R Appelbaum; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-03       Impact factor: 5.742

5.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Deborah A Thomas; Susan O'Brien; Rebecca Garris; Stefan Faderl; Xuelin Huang; Sijin Wen; Jan A Burger; Alessandra Ferrajoli; Partow Kebriaei; Richard E Champlin; Zeev Estrov; Pramoda Challagundla; Sa A Wang; Rajyalakshmi Luthra; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

6.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.

Authors:  Valentino Conter; Claus R Bartram; Maria Grazia Valsecchi; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Maurizio Aricò; Martin Zimmermann; Georg Mann; Giulio De Rossi; Martin Stanulla; Franco Locatelli; Giuseppe Basso; Felix Niggli; Elena Barisone; Günter Henze; Wolf-Dieter Ludwig; Oskar A Haas; Giovanni Cazzaniga; Rolf Koehler; Daniela Silvestri; Jutta Bradtke; Rosanna Parasole; Rita Beier; Jacques J M van Dongen; Andrea Biondi; Martin Schrappe
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.

Authors:  V H J van der Velden; D C H Jacobs; A J M Wijkhuijs; W M Comans-Bitter; M J Willemse; K Hählen; W A Kamps; E R van Wering; J J M van Dongen
Journal:  Leukemia       Date:  2002-08       Impact factor: 11.528

9.  Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Partow Kebriaei; Elias Jabbour; Michael Rytting; Sergernne York; Farhad Ravandi; Rebecca Garris; Monica Kwari; Stefan Faderl; Jorge Cortes; Richard Champlin; Susan O'Brien
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

10.  Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.

Authors:  David O'Connor; Amir Enshaei; Jack Bartram; Jeremy Hancock; Christine J Harrison; Rachael Hough; Sujith Samarasinghe; Claire Schwab; Ajay Vora; Rachel Wade; John Moppett; Anthony V Moorman; Nick Goulden
Journal:  J Clin Oncol       Date:  2017-11-13       Impact factor: 44.544
View more
  21 in total

1.  Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Authors:  Lori Muffly; Emily Curran
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.

Authors:  Elias J Jabbour; Koji Sasaki; Farhad Ravandi; Nicholas J Short; Guillermo Garcia-Manero; Naval Daver; Tapan Kadia; Marina Konopleva; Nitin Jain; Jorge Cortes; Ghayas C Issa; Jovitta Jacob; Monica Kwari; Philip Thompson; Rebecca Garris; Naveen Pemmaraju; Musa Yilmaz; Susan M O'Brien; Hagop M Kantarjian
Journal:  Cancer       Date:  2019-04-15       Impact factor: 6.860

3.  Expression of proliferation-related genes in BM-MSC-treated ALL cells in hypoxia condition is regulated under the influence of epigenetic factors in-vitro.

Authors:  Xiaoyu Yang; Yan Wang; Heshu Sulaiman Rahman; Talar Ahmad Merza Mohammad; Amin Daei Sorkhabi; Stanislav Evgenievich Korsakov; Lakshmi Thangavelu; Ali Adili; Aila Sarkesh; Rozita Tamjidifar; Hossein Saeedi; Ramin Aslaminabad; Saeed Tarzi; Morteza Akbari
Journal:  Med Oncol       Date:  2022-05-18       Impact factor: 3.064

4.  MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

Authors:  Nicola Gökbuget
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 5.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

6.  Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

Authors:  Lori Muffly; Vandana Sundaram; Connie Chen; Ilana Yurkiewicz; Eric Kuo; Sarah Burnash; Jay Y Spiegel; Sally Arai; Matthew J Frank; Laura J Johnston; Robert Lowsky; Everett H Meyer; Robert S Negrin; Andrew R Rezvani; Surbhi Sidana; Parveen Shiraz; Judith A Shizuru; Wen-Kai Weng; Michaela Liedtke; Hyma T Vempaty; David B Miklos
Journal:  Blood Adv       Date:  2021-08-24

7.  Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Naohito Fujishima; Toshiki Uchida; Yasushi Onishi; Chul Won Jung; Yeow Tee Goh; Kiyoshi Ando; Ming Chung Wang; Chiho Ono; Miyako Matsumizu; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Yosuke Fujii; Masayuki Hino
Journal:  Int J Hematol       Date:  2019-11-13       Impact factor: 2.490

Review 8.  MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.

Authors:  Manuela Tosi; Orietta Spinelli; Matteo Leoncin; Roberta Cavagna; Chiara Pavoni; Federico Lussana; Tamara Intermesoli; Luca Frison; Giulia Perali; Francesca Carobolante; Piera Viero; Cristina Skert; Alessandro Rambaldi; Renato Bassan
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 9.  Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.

Authors:  Alexander Gavralidis; Andrew M Brunner
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

Review 10.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.

Authors:  Nicholas J Short; Hagop Kantarjian; Elias Jabbour
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 12.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.